Abstract:Objective To investigate the expression of miR-126 and the levels of fibroblast growth factor 23 (FGF-23),plasma pentaxin 3 (PTX3) and Galectin-3 in patients with chronic kidney disease (CKD) complicated with major adverse cardiovascular events (MACE) and their clinical significance. Methods A total of 92 patients with stage 3 to 5 CKD treated from January 2017 to January 2019 were selected and divided into MACE group and non-MACE group (control group) according to whether MACE occurred in them within 6 months.In the same period,60 healthy people were served as the healthy group.The expression of miR-126 and the levels of FGF-23,PTX3 and Galectin-3 were compared in the patients with different CKD stages and among three groups,and their correlations were analyzed. Results The incidences of MACE were 17.9%,33.3% and 56.5% in CKD stage 3,4 and 5,respectively and increased significantly with the increase of CKD stage(χ²=9.806,P=0.006).With the increase of CKD stage,the expression of miR-126 decreased,and the levels of FGF-23,PTX3 and Galectin-3 increased significantly(all P<0.01).There were significant differences in the expression of miR-126 and the levels of FGF-23,PTX3 and Galectin-3 among three groups (all P<0.01).Pearson correlation analysis showed that miR-126 expression in CKD patients with MACE was negatively correlated with FGF-23(r=-0.551,P=0.000),PTX3(r=-0.506,P=0.000) and Galectin-3 (r=-0.496,P=0.000),respectively. Conclusion There is a obvious correlation among miR-126,FGF-23,PTX3 and Galectin-3 in CKD patients complicated with MACE,which is of great significance for exploring the mechanism of MACE in CKD patients.